Vensica Medical Overview
Vensica is developing ViXe, a product that combines Xeomin, a commercial neurotoxin, and Vibe, a breakthrough, needle-free, ultrasound drug delivery device. Vibe is a breakthrough platform designed to deliver drugs directly into the bladder wall, providing uniform, controlled and localized treatments for urology applications. Vibe leverages a disruptive ultrasound technology to deliver drugs through the natural barriers of the urinary bladder. By generating cavitation bubbles, Vibe precisely microinjects the drugs into the bladder wall, ensuring a controlled and uniform delivery of medications and biologics.
Cumulative Funding Raised Over Time ($)
$700KAug 2014
$3.7MFeb 2022
$4.2MJul 2016
$20.2MNov 2021
$31.2MOct 2024
$33.2MSep 2017
Latest News
growth-positive
/PRNewswire/ -- Vensica Medical ("Vensica"), a pioneering urology therapeutics company, today announced the successful closing of an $11 million funding round....
Vensica Medical, a urology therapeutics company, has secured $11 million in funding to advance its needle-free delivery system for botulinum toxin A (Xeomin®) aimed at treating overactive bladder (OAB). The investment, led by Israel Biotech Fund with strategic partners Merz and Laborie, will support Phase 2 clinical trials in the US and Europe. Vensicas technology offers a minimally invasive alternative to traditional injections, potentially transforming OAB treatment. The partnership with Merz grants Vensica exclusive rights to Xeomin® for needle-less applications in urology, enhancing their clinical development efforts.
InvestmentPartners
growth-positive
Vensica Closes $19 Million Round with Investment from Strategic Partner Merz
Vensica Therapeutics has closed a $19 million investment round, with participation from Merz Group. Vensica is a clinical stage biopharmaceutical company that is developing a needle-free drug delivery platform for urological indications. The funds raised will support the companys phase II clinical trials in Europe and the USA. Vensica is also expanding its workforce in Israel for the next stage of clinical and regulatory development. The investment from Merz Group reflects their commitment to establishing a urology treatment platform and their strategic partnership with Vensica. The article highlights the potential of Vensicas needle-free platform to improve the patient experience and enable more efficacious treatment. The companys CEO and the CEO of Merz Therapeutics both express optimism about the collaboration and the development of less invasive treatments for bladder diseases.
InvestmentPartners
growth-positive
Vensica Therapeutics Closes $16 Million Investment Round
Vensica Therapeutics, a clinical stage biopharmaceutical company, has closed an investment round of $16 million. The investment round was led by Israel Biotech Fund (IBF) and included other investors such as Laborie, Lew Pell, Agriline, and The Trendlines Group. The funds raised will support the companys phase II multicenter clinical trials in Europe and the USA. Vensica Therapeutics has also signed a strategic license and collaboration agreement with Merz Therapeutics, licensing Merzs botulinum neurotoxin A (XEOMIN®) for needle-free use in urological procedures. The company plans to expand its workforce in Israel for the next stage of clinical and regulatory development. Vensicas needle-free platform for drug delivery aims to provide a less invasive and more effective treatment for bladder diseases, including overactive bladder.
Investment
Merz and Israeli Start-Up Vensica Launch Partnership for Needleless Treatment of Overactive Bladder
growth-positive
Cogentix Medical Makes $2 Million Investment in Israeli Company Developing Innovative and Novel Device for Delivery of Drugs to the Bladder
Cogentix Medical has announced a $2 million investment in Vensica Medical, an Israeli-based company developing an ultrasound-based, needle-free drug delivery system called VensiCare. The initial indication for VensiCare will be the delivery of botulinum toxin to treat overactive bladder. Cogentix will receive one seat on the Vensica Board and options to acquire the entire company for an additional $8 million. Cogentix sees the potential of VensiCare to revolutionize the administration of botulinum toxin for overactive bladder and believes it could be a broad-based drug delivery platform for other indications, such as cancer. This investment is part of Cogentixs strategy to prudently invest its cash in a variety of transactions, including acquisition, licensing, and development agreements.
Investment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $33.2M |
| Last funding | $11M |
| Stage | Seed |
| Rounds | 6 |
| Investors | 9 |
Team Members
2
Employees: 11-50
Web & Social Links
| Website | vensica.com |
Locations
HaGavish Street 4, Netanya, Israel
New York, NY, USA
Photos & Videos
1 item(s)
Vensica Medical Business
Business models
B2B
Product stage
Clinical Trial
Employees
11-50
Sector
Health Tech & Life SciencesMedical DevicesMedical Treatment & TherapeuticsTarget Customer
Healthcare & Life SciencesHealthcareProvidersCore Technology
Simulation & ImagingUltrasoundTags (13)
hospitalscancerdrug-deliverymedical-devicesurinary-systemcathetersultrasoundoncologyurologyminimally-invasivepain-freetreatmentsbioconvergenceGeographic Markets
GlobalVensica Medical Financials
$33.2M
Total funding
Undisclosed
Capital raised
$11M
Last funding
Seed
Funding stage
6
Total rounds
9
Investors
Cumulative Funding Raised Over Time ($)
$700KAug 2014
$3.7MFeb 2022
$4.2MJul 2016
$20.2MNov 2021
$31.2MOct 2024
$33.2MSep 2017
Private Equity Funding
Undisclosed Round
Oct 2024
$11M
Israel Biotech Fund (Lead)
Undisclosed Round
Feb 2022
$3M
Merz Therapeutics
Undisclosed Round
Nov 2021
$16M
Israel Biotech Fund (Lead)
,
Laborie Medical Technologies, The Trendlines Group, Agriline, Lewis Pell
Undisclosed Round
Sep 2017
$2M
Cogentix Medical (Lead)
,
Accelmed
Seed
Jul 2016
$500K
Undisclosed Investor(s)
Seed
Aug 2014
$700K
The Trendlines Group
Vensica Medical Lifecycle
Cumulative Funding Raised Over Time
$700KAug 2014
$3.7MFeb 2022
$4.2MJul 2016
$20.2MNov 2021
$31.2MOct 2024
$33.2MSep 2017
All Events
Undisclosed Round
Oct 2024
$11M
Israel Biotech Fund (Lead)
Undisclosed Round
Feb 2022
$3M
Merz Therapeutics
Undisclosed Round
Nov 2021
$16M
Israel Biotech Fund (Lead)
,
Laborie Medical Technologies, The Trendlines Group, Agriline, Lewis Pell
Undisclosed Round
Sep 2017
$2M
Cogentix Medical (Lead)
,
Accelmed
Seed
Jul 2016
$500K
Undisclosed Investor(s)
Seed
Aug 2014
$700K
The Trendlines Group
Vensica Medical News
6 articles
growth-positive
/PRNewswire/ -- Vensica Medical ("Vensica"), a pioneering urology therapeutics company, today announced the successful closing of an $11 million funding round....
Vensica Medical, a urology therapeutics company, has secured $11 million in funding to advance its needle-free delivery system for botulinum toxin A (Xeomin®) aimed at treating overactive bladder (OAB). The investment, led by Israel Biotech Fund with strategic partners Merz and Laborie, will support Phase 2 clinical trials in the US and Europe. Vensicas technology offers a minimally invasive alternative to traditional injections, potentially transforming OAB treatment. The partnership with Merz grants Vensica exclusive rights to Xeomin® for needle-less applications in urology, enhancing their clinical development efforts.
InvestmentPartners
growth-positive
Vensica Closes $19 Million Round with Investment from Strategic Partner Merz
Vensica Therapeutics has closed a $19 million investment round, with participation from Merz Group. Vensica is a clinical stage biopharmaceutical company that is developing a needle-free drug delivery platform for urological indications. The funds raised will support the companys phase II clinical trials in Europe and the USA. Vensica is also expanding its workforce in Israel for the next stage of clinical and regulatory development. The investment from Merz Group reflects their commitment to establishing a urology treatment platform and their strategic partnership with Vensica. The article highlights the potential of Vensicas needle-free platform to improve the patient experience and enable more efficacious treatment. The companys CEO and the CEO of Merz Therapeutics both express optimism about the collaboration and the development of less invasive treatments for bladder diseases.
InvestmentPartners
growth-positive
Vensica Therapeutics Closes $16 Million Investment Round
Vensica Therapeutics, a clinical stage biopharmaceutical company, has closed an investment round of $16 million. The investment round was led by Israel Biotech Fund (IBF) and included other investors such as Laborie, Lew Pell, Agriline, and The Trendlines Group. The funds raised will support the companys phase II multicenter clinical trials in Europe and the USA. Vensica Therapeutics has also signed a strategic license and collaboration agreement with Merz Therapeutics, licensing Merzs botulinum neurotoxin A (XEOMIN®) for needle-free use in urological procedures. The company plans to expand its workforce in Israel for the next stage of clinical and regulatory development. Vensicas needle-free platform for drug delivery aims to provide a less invasive and more effective treatment for bladder diseases, including overactive bladder.
Investment
Merz and Israeli Start-Up Vensica Launch Partnership for Needleless Treatment of Overactive Bladder
growth-positive
Cogentix Medical Makes $2 Million Investment in Israeli Company Developing Innovative and Novel Device for Delivery of Drugs to the Bladder
Cogentix Medical has announced a $2 million investment in Vensica Medical, an Israeli-based company developing an ultrasound-based, needle-free drug delivery system called VensiCare. The initial indication for VensiCare will be the delivery of botulinum toxin to treat overactive bladder. Cogentix will receive one seat on the Vensica Board and options to acquire the entire company for an additional $8 million. Cogentix sees the potential of VensiCare to revolutionize the administration of botulinum toxin for overactive bladder and believes it could be a broad-based drug delivery platform for other indications, such as cancer. This investment is part of Cogentixs strategy to prudently invest its cash in a variety of transactions, including acquisition, licensing, and development agreements.
Investment
growth-positive
Bladder treatment co Vensica raises $500,000
Israeli startup Vensica Medical has closed a $500,000 financing round from a private foreign investor. The company is developing a needle-free, painless procedure for the delivery of Botox to treat overactive bladder. The investment will be used for R&D and completion of device design. Overactive bladder affects millions of people and Vensicas approach aims to improve the quality of life for those suffering from the condition.
Investment
Employee Info
| Employees (range) | 11-50 |
| Exact count | 11 |
| Team members | 2 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 8 classification IDs that could be used for matching.
Vensica Medical Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 99/100 |
| Missing | markets |
| BI Verification | Sharon Shapira |
| Registrar ID | 515110765 |
| Crunchbase | vensica-medical |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2024-10-29T00:00:00.000Z |
| Created | 2014-12-15T00:00:00.000Z |
| Claimed | Yes |